{'fraction_non_alphanumeric': 0.035576923076923075, 'fraction_numerical': 0.0125, 'mean_word_length': 5.3090909090909095, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Antiangiogenic therapies in gastric cancer: trusting the pathway.

Gastric cancer (GC) represents a worldwide problem being the third leading cause of cancerdeath 1 . Most patients present with an advanced stage at diagnosis and require systemic treatment. While chemotherapy has shown a limited effect 2 , molecularly-driven therapies are urgently needed. In the article that accompanies this editorial, Yoon et al. 3 report negative results of a randomized, placebo-controlled, double-blind phase II study with ramucirumab, the fully human monoclonal antibody directed to the vascular endothelial growth factor receptor 2 (VEGFR-2). These results contrast with the demonstrated mild but positive effects of antiangiogenic therapies in GC 4-8 . The large number of oesophageal cancer (EC) patients included in this study (48%), and the high rate of premature non-progressive disease discontinuations in the experimental arm (54%) compared with the control arm (22%), could partially explain the differential outcome observed in this study.